Transforming growth factor-beta1 SNPs: genetic and phenotypic correlations in progressive kidney insufficiency.
Associations have been described between polymorphisms of cytokine and growth factor genes and susceptibility to, or progression of, an increasing number of diseases. TGF-beta1 plays an important role in the pathogenesis of experimental and clinical glomerulosclerosis and tubulointerstitial fibrosis. In this study, single nucleotide polymorphisms (SNPs) in the TGFbeta1 gene were investigated as possible markers for the progression of chronic kidney failure (CKF). 145 Caucasian patients with CKF were screened for four TGFbeta1 SNPs: T-509C in the promoter region; Arg25Pro and Leu10Pro in exon 1 and Thr263Ile in exon 5. There were significant differences between CKF patients and controls in allele frequencies of two of the SNPs, Leu10Pro (p = 0.038) and C-509T (p = 0.02) and in haplotype distributions (p = 0.0175), indicating an association with susceptibility to CKF. We also observed a significant association between progression of CKF and homozygosity for Arg25 (odds ratio 3.77, 95% confidence interval 1.57-9.04, p = 0.002). Homozygosity for Arg25 was also associated with severity of proteinuria at diagnosis (p = 0.038), plasma TGF-beta1 protein levels (p = 0.01), and severity of glomerulosclerosis (p = 0.04). Homozygosity for -509T was associated with severity of proteinuria at diagnosis (p = 0.0017), level of renal tubular TGF-beta1 immunostaining (p = 0.0006) and with severity of renal interstitial inflammatory cellular infiltration (p = 0.01). Tubular TGF-beta1 immunostaining was significantly higher in biopsies with inflammatory cellular infiltration compared those without inflammation (p = 0.0048). There was a significant difference in haplotype distributions between CKF patients with progressive, as opposed to non-progressive disease (p = 0.0484). TGFbeta1 SNPs may be useful prognostic indicators for the progression of CKF.
Khalil
M Salah
MS
Biomedical Science Research Centre, Sheffield Hallam University, Sheffield, UK.
El Nahas
A M
AM
Blakemore
A I F
AI
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001120:Arginine; D016022:Case-Control Studies; D003596:Cytosine; D018450:Disease Progression; D005260:Female; D005355:Fibrosis; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D005923:Glomerulosclerosis, Focal Segmental / Q000473:pathology; D006239:Haplotypes; D006720:Homozygote; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D007668:Kidney / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000235:genetics* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D020641:Polymorphism, Single Nucleotide; D011392:Proline; D012720:Severity of Illness Index; D013194:Staining and Labeling; D013941:Thymine; D016212:Transforming Growth Factor beta / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D053773:Transforming Growth Factor beta1
C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D003596:Cytosine; D001120:Arginine; D011392:Proline; D013941:Thymine